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Significance of their study
What is already known about this subject?
 ► Molecular profiling of routine cancer specimens 
is both increasingly common and increasingly 
complex, requiring considerable expertise to distil 
the most relevant findings and make appropriate 
recommendations.
What does this study add?
 ► A multidisciplinary genomics review board (GRB) of 
clinicians is able to make appropriate recommen-
dations regarding the stratification of patients for 
established therapy, referral to clinical trials, clinical 
genetics review and advise on further testing.
How might this impact on clinical practice?
 ► The experience of the Sarah Cannon Research 
Institute GRB provides a framework for the delivery 
of this service and highlights the challenges fre-
quently encountered when reviewing molecular pro-
filing results from patients with a range of tumour 
types.
AbStrAct
Background The increasing frequency and complexity 
of cancer genomic profiling represents a challenge for 
the oncology community. Results from next-generation 
sequencing–based clinical tests require expert review to 
determine their clinical relevance and to ensure patients 
are stratified appropriately to established therapies or 
clinical trials.
Methods The Sarah Cannon Research Institute UK/UCL 
Genomics Review Board (GRB) was established in 2014 
and represents a multidisciplinary team with expertise in 
molecular oncology, clinical trials, clinical cancer genetics 
and molecular pathology. Prospective data from this board 
were collated.
Results To date, 895 patients have been reviewed by the 
GRB, of whom 180 (20%) were referred for clinical trial 
screening and 62 (7%) received trial therapy. For a further 
106, a clinical trial recommendation was given.
Conclusions Numerous challenges are faced in 
implementing a GRB, including the identification of 
potential germline variants, the interpretation of variants of 
uncertain significance and consideration of the technical 
limitations of pathology material when interpreting 
results. These challenges are likely to be encountered 
with increasing frequency in routine practice. This GRB 
experience provides a model for the multidisciplinary 
review of molecular profiling data and for the linking of 
molecular analysis to clinical trial networks.
IntRoduCtIon
The field of cancer genomics has progressed 
rapidly in recent years with a growing use 
of molecular profiling, partly driven by an 
increasing accessibility to commercial and 
academic providers and the evolution from 
single-gene assays to massively parallel DNA 
sequencing, also known as next-generation 
sequencing (NGS).1–3 The implementation 
of NGS use for routine clinical samples is a 
significant step towards the personalisation of 
cancer medicine and is due to considerable 
reduction in time and cost of DNA sequencing, 
allowing for a growing implementation of 
genomics in cancer diagnosis and prediction 
of response to therapy, via the identification 
of molecular alterations within tumour cells 
which are associated with targeted cancer 
treatments such as protein kinase inhibitors 
and monoclonal antibodies.4 5 The growing 
use of NGS poses a challenge on how to prop-
erly interpret the vast output of data, merge it 
with existing knowledge databases and trans-
late it into valid therapeutic decisions.6 7 Clin-
ically, there is a need for increasing genomic 
literacy—one study of 160 physicians in a 
tertiary care National Cancer Institute–desig-
nated comprehensive cancer centre reported 
22% of physicians having low confidence in 
genomic knowledge.8 As adoption rates of 
incorporating NGS technology into clinical 
practice continue to rise,9 there is a need for 
expert analysis of NGS results to assess the use 
of these data in the context of an individual 
patient.
The implementation of genomics-driven 
cancer medicine, including the technical 
infrastructure required and challenges faced, 
have been well described, confirming broad 
implementation of NGS testing in a clinical 
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Physician to ensure all information provided 
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coordination of the GRB meeting, completion 





Responsible for advising appropriate onward 
genetic counselling and testing based 





Responsible for reviewing pathology reports 
and for liasing between the GRB and the 
SCMD molecular pathology laboratory
SCMD, Sarah Cannon Molecular Diagnostics; SCRI, Sarah Cannon 
Research Institute.
setting is feasible.10–12 For example, at Sarah Cannon 
Research Institute (SCRI) US, 936 patients with advanced 
cancers underwent NGS to guide clinical trial selec-
tion—of the 103 patients who were enrolled on clinical 
trials—50 of these patients were enrolled onto clinical 
trials matched to mutational status.13 NGS technologies 
typically generate far larger volumes of data than is usual 
in clinical tests and these data require expert interpre-
tation if these data are to be used appropriately in the 
clinical setting.
Although well established in the USA, molecular 
tumour boards (MTBs) are not extensively established 
in UK practice. Following the completion of the 100K 
Genomes Project and subsequent establishment of The 
NHS National Genomic Test Directory, molecular testing 
of adult solid tumours through genomic medicine hubs 
using NGS is likely to require increasing MTB input in the 
management of routine cases.
A Genomics Review Board (GRB) was established 
at SCRI in August 2014 UK by assembling experts in 
oncology, clinical genetics and molecular pathology to 
scrutinise molecular profiling results, setting a standard 
for quality interpretation. The GRB currently consists of 
GRB physicians, a molecular oncologist, a clinical genet-
icist, a molecular pathologist and a GRB coordinator 
(see table 1). The SCRI UK GRB interprets molecular 
profiling results for clinicians, thoroughly assesses the 
validity of the results alongside patient medical informa-
tion, including a review, where relevant, of the variant 
allele frequency (VAF) of detected variants in relation to 
tumour content in the pathology sample. It also identi-
fies potential patients for clinical trials and makes recom-
mendations where appropriate for clinical genetics 
review.
This report represent the prospective analysis of 
cases reviewed by a solid tumour GRB over its first 45 
months of activity. The breakdown of cases reviewed, 
profiling outcomes for those tested in the local molecular 
pathology laboratory, recommendations given and clin-
ical trial recruitment are described. In light of this GRB 
experience, the challenges faced in bridging molecular 
profiling findings with making recommendations for 
patient therapy are discussed.
MetHods
All cases reviewed by the GRB from 11 August 2014 to 
the cut-off date of 7 May 2018 were prospectively assessed 
and included in the cohort. Data were collated regarding 
tumour type, the molecular profiling test reviewed, 
recommendations given by the GRB and clinical trial 
recruitment where available. Additional data regarding 
driver mutations and samples effected by formalin arte-
fact were collated for all cases where multigene panel 
testing had been performed in the local molecular diag-
nostic laboratory associated to the GRB.
GRB process
Molecular profiling reports were submitted to the GRB 
coordinator, either directly from treating physicians or as 
part of the genetic testing pathway from the healthcare 
provider. Concise patient clinical summaries and family 
histories where appropriate were collated for GRB review, 
and were distributed to the GRB membership alongside 
NGS reports weekly for review the following working day 
by teleconference. The GRB molecular oncologist exam-
ined the results in the context of the patient’s clinical 
and family history, specimen tumour content, detected 
variants and the VAF. These were also reviewed by the 
GRB clinical geneticist to determine whether the patient 
requires clinical genetics review in light of the detected 
variants and the wider clinical context. The variants were 
evaluated, with reference to the published literature and 
conference abstracts, Catalogue of Somatic Mutations in 
Cancer (COSMIC) database and other single-nucleotide 
polymorphism (SNP) databases such as Exome Aggrega-
tion Consortium (ExAC) database, International Agency 
for Research on Cancer (IARC), the gastrointestinal 
malignancy variant database InSiGHT, the archive of 
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Table 2 Level evidence scale for target prioritisation—adapted from Andre et al2
Level of evidence A B C Clinical implications
I: Molecular alteration 
validated in several 
robust early phase trials 
or at least one phase III 
randomised trial
Alteration validated 
in the disease under 
consideration, targeted 
therapies have shown to 
be ineffective in patients 
who are lacking the 
genomic alteration
No evidence that 
the therapy does not 
work in the absence 
of the molecular 
alteration
Level I molecular 
alteration, but not in 
the disease under 
consideration
A/B: Patients must 
be treated with the 
targeted therapy
C: Patients must enter 
clinical trials testing 
the targeted therapy
II: Molecular alteration 




in the disease under 
consideration, targeted 
therapies have shown to 
be ineffective in patients 
who are lacking the 
genomic alteration
No evidence that 
the therapy does not 
work in the absence 
of the molecular 
alteration
Level I molecular 
alteration, but not in 
the disease under 
consideration
Patients must enter 
clinical trials testing 
the targeted therapy
III : Target suggested by 
preclinical studies
Preclinical studies include 
human samples, cell lines 
and animal models
Preclinical studies 
that lack either 
cell lines or animal 
models
NA Inclusion in clinical 
trials is optional
IV: Target predicted 
but lack of clinical or 
preclinical data




is not known as 
cancer-related gene
NA Inclusion in clinical 
trials is optional
NA, not available.
clinically relevant variants ClinVar and the cancer predis-
position gene Variant Database (CAVADA). Reviews of 
recent conference proceedings and the use of algorithms 
including Polyphen and Sorts Intolerant From Tolerant 
(SIFT) algorithms were used to predict whether a 
particular mutation may be deleterious. This information 
was then collated and discussed at the GRB, with results 
fed back to the referring physician, typically the same day, 
including identification of any actionable mutation targ-
etable by a drug as per the level of evidence for target 
prioritisation,2 and whether the patient may have be suit-
able for a clinical trial (see table 2). Where a recommen-
dation was made for clinical genetics referral, this was 
also fed back through the GRB co-ordinator.
somatic variant analysis
Multigene panel testing provided at the molecular diag-
nostic facility aligned to the GRB, Sarah Cannon Molec-
ular Diagnostics (SCMD), was performed using the 
CE-IVD marked Oncomine solid tumour NGS panel 
(Life Technologies, Carlsbad, California, USA) run on 
the IonTorrent Personal Genome Machine (PGM). All 
specimens were received as formalin-fixed, paraffin-em-
bedded tissue blocks, unstained slides or tissue curls. 
All specimens received as blocks and slides underwent 
preanalytical pathological assessment to estimate tumour 
cell fraction and to ensure there was sufficient material 
to process for DNA extraction. Samples over 5% tumour 
cell fraction were accepted for analysis. Following DNA 
extraction, the target regions were amplified, barcoded 
and then sequenced on the PGM. Data were analysed 
using a hybrid bioinformatics pipeline incorporating 
both Torrent Suite VariantCaller (V.5.0.4.0) and in-house 
developed software. This pipeline ultimately generated 
draft clinical reports which assigned an analytical status 
to >5000 hotspot variants. Hotspot variants were defined 
as unique coding variants in the COSMIC database (V.79) 
which mapped to the gene panel. Prior to manual review 
of the draft clinical reports, all variants above 2.5% VAF 
which met required quality thresholds were classified 
as detected. Variants below 1% VAF were classified as 
not detected, and variants between 1% and 2.5% VAF 
or those not meeting the necessary quality thresholds 
(regardless of VAF) were classed as equivocal variants. 
Prior to report authorisation and despatch, all reports 
underwent manual review by two independent assessors, 
during which the status of any variant could be reassigned 
if appropriate. Manual review also included the flagging 
of cases where the background level transition variants 
was indicated that certain observed variants may repre-
sent formalin fixation artefacts. Clinically appropriate 
comments were included in reports in light of the tumour 
type, detected variants, incidental finding and any poten-
tially relevant variants whose status remained equivocal. 
Turnaround time for this assay is typically between 7 and 
8 working days.14
In view of the heterogeneous group of patients 
receiving different targeted drugs and without any stan-
dard comparator for the respective disease, we have not 
formally assessed outcome.
Results
A total of 895 patients were prospectively reviewed as part 
of the GRB process over the 45 months studied. Non-small 
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Continued
cell lung cancer and colorectal cancer were the most 
common tumour types submitted and in combination 
these accounted for over half of the patients reviewed. An 
extensive breakdown of the tumour types reviewed by the 
GRB is given in table 3.
Of the 895 patients reviewed, 91 patients had multiple 
molecular profiling results reviewed, with a maximum of 
8, and the majority of these 91 patients were discussed at 
more than one GRB meeting. Seventy-six of the patients 
discussed had a recommendation made regarding an 
established therapy, based on genomic profiling results 
(8.5%). A total of 180 patients (20.1%) were referred to 
specific clinical trials at either SCRI (166) or UCLH (14) 
and a further 10 patients were referred to other trial sites. 
Of the 180, 58 were screened for trial at SCRI with 32 
subsequently enrolled onto and treated on a trial at SCRI. 
Five were screened at UCLH, with three enrolled and 
treated as part of a trial. A further 19 patients were treated 
on a trial at SCRI at a later time point, of whom 9 were 
enrolled onto the trial on the basis of their molecular 
profiling results. This gives a total of 73 patients enrolled 
on trials after GRB review.
Eight patients were not eligible for trials but were 
granted compassionate access to trial therapy at SCRI 
following GRB review. In total, therefore, 62 patients 
(7%) discussed at GRB received a trial therapy following 
GRB review.
For a further 106 patients, a general trial recommenda-
tions was included in the GRB report submitted to their 
clinician, but without a specific trial being identified. 
Due to the practicalities of the GRB operation and the 
lack of robust mechanisms for follow-up of many of the 
patients reviewed, it was not possible to determine how 
many of these recommendations led to trial referral and 
recruitment.
Clinical genetics referral was advised in 117 patients 
(13.1%) and further somatic molecular testing was 
advised in 94 patients (10.5%). The full breakdown of 
patients is given in figure 1.
Of all results reviewed by the SCRI GRB, the majority 
of reports were issued by SCMD, most of which used a 
diagnostic multigene panel (71%) and a smaller fraction 
single gene tests (4%). Of the gene panels, 38 of these 
represented a combined DNA and RNA somatic mutation 
and fusion panel. No positive fusion events were detected 
in this cohort. Other reports reviewed by the GRB were 
issued from Guardant ctDNA (9%), Foundation Medi-
cine (8%), Caris (3%) and the remainder issued from a 
range of other providers (5%).
Of the cases reported at SCMD, the proportion of cases 
showing driver mutations in the most commonly affected 
genes are shown in figure 2.
Breakdown of variants in MET and KRAS have been 
further detailed to exemplify the challenges in GRB anal-
ysis of these results, specifically the problems of variants of 
unknown significance in common drivers, and likely germ-
line variants which are reported as COSMIC-annotated 
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variants in assays where germline DNA is not tested for 
comparison.
The vast majority of driver mutations reported in KRAS 
occurred within codons 12 and 13, with other recognised 
drivers being located in codons 59, 61, 117 and 146. In 
the GRB review of SCMD reports, four KRAS mutations 
occurring outside of these codons were reported and 
were determined to be of uncertain clinical significance 
(see figure 3).
Several COSMIC-annotated variants from the reference 
genome in MET have been reviewed by the GRB following 
detection on molecular profiling, many of which are 
commonly reported at a VAF of around 50%, indepen-
dent of tumour fraction suggesting that they represent 
germline SNPs, as represented in figure 4. Due to the 
potential for SNPs to be misinterpreted as functional 
mutations, careful matching by the GRB with genome 
reference databases such as ExAC is critical.15
Of the 723 profiling results undergoing GRB review 
which were tested using a multigene panel at SCMD, 
88 (12.2%) had evidence of formalin fixation artefacts 
as was noted in the molecular pathology report. Over-
fixed samples were characterised by multiple transition 
variants (C>T, G>A) detected with a VAF above the limit 
of detection for the assay and not in keeping with the 
sample tumour fraction. Table 4 shows an example 
of detected variants from a sample with evidence of 
formalin fixation artefact. There was marked variation 
in the proportion of cases from differing institutions 
showing this signature, ranging from 0% to 26.9% in 
those centres submitting ≥10 cases, suggesting variation 
based on tissue processing protocols in different labora-
tories (see figure 5).
dIsCussIon
A number of challenges exist in correctly translating 
molecular profiling results for clinical implementation, 
making expert GRB review a vital process in patient strat-
ification.
Identification of potential germline variants and variants of 
unknown clinical significance
Most somatic variant analysis assays do not include parallel 
germline testing alongside tumour samples as part of the 
analysis, and this is not common practice currently in the 
UK, although there are some exceptions.16 17 The MSK-IM-
PACT study reported ‘presumed pathological germline 
variants’ in 15.7% of patients with advanced cancer.18 
Germline testing should ideally be performed following 
genetic counselling as results can have wide-ranging 
implications for patients and their families. Traditionally, 
germline testing is typically limited to those for whom 
the tumour in question is high risk for a specific genetic 
predisposition syndrome, such as in the Lynch screening 
pathway, or those with a relevant family history. Suspicious 
germline variants which may be clinically relevant are 
however frequently detected by somatic variant analysis, 
presenting with variant allele frequencies between 40% 
and 60%, reflecting germline heterozygosity. These may 
be germline variants seen frequently in the population, 
with no implications for cancer risk (SNPs), rarer variants 
with an unknown effect on risk or those which have been 
described as being relevant to cancer susceptibility.
This consideration highlights the importance of 
reporting tumour fraction and VAF in somatic variant 
analysis reports, as included in the SCMD multigene 
assays, or ideally analysing germline DNA in parallel. The 
GRB references online databases to determine whether a 
given mutation is likely to represent a somatic alteration 
frequently identified in cancer specimens or a germline 
mutation.
In a study conducted by Meric-Bernstam et al which 
consisted of 1000 patients undergoing somatic mutation 
screening using a 202-gene panel, pathogenic germline 
variants (PGVs) were identified in 43 patients of which 23 
were previously unrecognised and the remaining 20 vari-
ants were known to be pathogenic. The study also showed 
that 99% of patients indicated interest in being notified 
of these findings, and a protocol of determining whether 
the PGV results are significant and to be returned to 
the patient and the family, with genetic counselling, was 
established.19 20
It is crucial to consider the level of risk a particular PGV 
is likely to carry.20 For example, some PGVs have a well-de-
scribed association with an increased risk of cancer, while 
others are less well understood in their effect on cancer 
predisposition and consideration of an experienced GRB 
clinical geneticist is crucial for appropriate recommenda-
tions to be made.
Other variants which pose a challenge are variants 
of uncertain clinical significance (VUCSs). These are 
variants which are reported in cancer-associated genes, 
which appear to be genuine (ie, non-artefactual), but 
are not located in codons with well-described functional 
relevance. These variants may or may not confer a onco-
genic effect on the relevant gene.21–23 Recently published 
guidelines will provide an important resource in enabling 
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Figure 2 Number of reported cases with driver mutations 
in commonly affected cancer genes reported from Sarah 
Cannon Molecular Diagnostics multigene panel results.
Figure 3 Total number of KRAS variants identified and 
discussed by the Genomics Review Board from all Sarah 
Cannon Molecular Diagnostics reports. All recognised driver 
mutations in grey, variants of unknown clinical significance 
in black. KRAS variants identified as likely formalin fixation 
artefacts excluded.
Figure 4 MET variants identified in Sarah Cannon 
Molecular Diagnostics multigene panel testing with variant 
allele frequencies (VAFs). Several of these variants are 
consistently reported close to 50% VAF, which suggests 
these are likely single-nucleotide polymorphisms rather than 
tumour-specific mutations.
Table 4 Example of detected variants (COSMIC-annotated 
coding variants at >2.5% VAF) from a single sample with 





AKT1 p.(Pro51Leu), c.152 C>T, COSM4468165 4%
BRAF p.(Gly466Glu), c.1397 G>A, COSM453 3%
BRAF p.(Asp587Asn), c.1759 G>A, 
COSM21608
3%
CTNNB1 p.(Ala21Val), c.62 C>T, COSM1422998 3%
CTNNB1 p.(Trp25*), c.74 G>A, COSM3593969 3%
DDR2 p.(Gly584Arg), c.1750 G>A, 
COSM5446941
4%
EGFR p.(Glu872Lys), c.2614 G>A, 
COSM133589
3%
SMAD4 p.(Ser171Leu), c.512 C>T, 
COSM5610594
3%
TP53 p.(His168Arg), c.503 A>G, COSM43545 34%
TP53 p.(Glu285Lys), c.853 G>A, COSM10722 4%
9 of 10 detected variants are low frequency (<5% VAF) transition 
variants (C>T or G>A), indicating likely formalin fixation artefact in 
the sample, with one apparent genuine tumour-specific variant: 
TP53 p.(His168Arg).
VAF, variant allele frequency.
newly established GRBs to classify reported variants 
appropriately.24 25
Established driver KRAS mutations are predictors 
of resistance to anti-EGFR therapy in both lung and 
colorectal cancer. Where the KRAS mutation is of uncer-
tain clinical significance with no functional evidence in 
the literature of pathogenicity, the GRB cannot posi-
tively warrant refraining from anti-EGFR therapy options. 
VUCSs can also be found in cancer predisposition genes 
and this requires a decision to be made as to whether a 
VUCS should be followed up with confirmatory testing of 
the germline.
As molecular profiling becomes even more prevalent 
and population-level tumour genomic profiling data are 
available, the role of many variants whose clinical signifi-
cance is currently unknown is likely to be elucidated.
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Figure 5 Proportion of cases demonstrating formalin-
fixed, paraffin-embedded artefact from the six main 
referring institutions referring samples to Sarah Cannon 
Molecular Diagnostics which were then discussed at the 
Genomics Review Board (range, 0%–26.9%).
tumour heterogeneity
Tumour heterogeneity presents another challenge in 
determining whether a given mutation is a relevant driver 
in oncogenesis or is a subclonal event, arising de novo 
in an expanding tumour, reflecting the branched clonal 
evolution of the tumour.3 26 As an example, in EGFR-
driven lung cancer, subclonal T790M mutation occurs as 
a resistance mechanism to EGFR tyrosine kinase inhibi-
tors following treatment, representing a subclonal muta-
tion with crucial clinical relevance. Subclonal mutations 
may show lower variant allele frequencies than clonal 
mutations, although any difference may depend on the 
size of the subclone, local DNA copy number aberrations, 
and how this relates to the resection or biopsy specimen 
which has been sampled in the sequencing assay. Since 
the content of the tumour can change rapidly with time, 
it is helpful to compare molecular profiling of samples 
collected recently with any previous results to identify 
the emergence of subclonal mutations. Indeed, compar-
ison of primary and metastatic tumour samples profiled 
at different time points can also help confirm that they 
are clonally related and do not represent dual primary 
tumours. The GRB determines the likelihood that a 
particular mutation might be subclonal and the relevance 
of this to selection of treatment. Significant changes can 
be seen between specimens taken from the same tumour 
at different time points and from different biopsy sites.
Fixation artefacts
Surgical pathology specimens are routinely fixed in 
formalin, processed through alcohol and embedded 
in paraffin to aid histopathological processes and to 
preserve the tissue indefinitely. The majority of tumour 
molecular profiling is currently performed on specimens 
which have been processed in this way. Formalin fixa-
tion has a range of effects on DNA and RNA including 
deamination of nucleotides causing artefactual transition 
variants (cytosine to thymine and guanine to adenine). 
Specimens which have been fixed in formalin for longer 
show much greater numbers of transition type variants27 
and in somatic variant analysis fixation artefacts can be 
falsely interpreted as genuine somatic mutations. Over-
fixed specimens usually demonstrate multiple back-
ground mutations with VAFs <10% on multigene molec-
ular profiling. The GRB identifies cases with this signa-
ture and interprets molecular profiling results with these 
considerations in mind such that GRB reports reflect this 
issue.
Identifying actionable mutations and feedback of results
If an oncogenic somatic mutation has been identified, the 
GRB is required to determine whether this can be effec-
tively targeted by a therapeutic agent. Some activating 
mutations are established predictors of standard of care 
targeted therapies, while other mutations identified from 
cancer genomic profiling can potentially stratify patients 
for clinical trials and the GRB has the ability to link these 
patients with relevant clinical trials, with rates of trial 
referrals and trial recruitment detailed above. Although 
follow-up in this cohort is not entirely comprehensive, 
specifically the breadth of referrals making it impossible 
to know how many general trial recommendations led to 
recruitment and the lack of robust outcome data for those 
patients reviewed, the size of the cohort and the detailed 
local trial recruitment and clinical genetic referral data do 
highlight the potential for stratifying patients uniformly 
and effectively using molecular profiling data.
Where a driver mutation is identified which is not a 
marker of response to a standard of care treatment, the 
availability of a suitable clinical trial and the logistics 
of linking patients with the centres offering these trials 
present further challenges for GRBs and co-ordinators 
of patients with cancer. However, with an increasing 
use of GRBs in clinical institutions, supported by the 
UK NHS Genomic Medicine Service recommendation 
for Genomic Tumour Advisory Boards to be established 
across NHS Trusts as an integral part of the cancer 
pathway, it should be possible to expand the communica-
tion between molecular profiling laboratories, clinics and 
clinical trial centres, allowing patients greater access to 
suitable clinical trials targeting their specific mutations. 
In addition, in UK practice, this may help to identify 
patients suitable for therapy outside of either through 
compassionate access programmes or the NHS Cancer 
Drug Fund.
At present, molecular profiling is not well integrated 
into routine pathology in the UK and as such comprehen-
sive review of patients typically requires the manual colla-
tion of reports from across unconnected laboratories. The 
GRB co-ordinator is therefore crucial in ensuring that the 
clinically relevant data are available. Ideally, pathology 
reporting systems would allow for combined reporting, 
 o
n






pen: first published as 10.1136/esm
oopen-2018-000469 on 21 M
arch 2019. Downloaded from
 
Open access
9Moore DA, et al. ESMO Open 2019;4:e000469. doi:10.1136/esmoopen-2018-000469 Moore DA, et al. ESMO Open 2019;4:e000469. doi:10.1136/esmoopen-2018-000469
able to ensure that all relevant information for patients 
can be delivered as fully integrated pathology reports.
The data extracted from this large cohort do question 
the need for applying broad NGS panels as a routine 
test and the limited number of actionable alterations, 
even within the clinical trials environment, suggests that 
using more focused NGS panels for first-line molecular 
profiling is more appropriate.
Molecular profiling reports vary widely between 
providers and reports from some providers can include 
large quantities of data which may not be clearly 
presented, making these complex and difficult for clini-
cians to interpret. The GRB serves to help clinicians 
interpret these results, discerning between therapeuti-
cally relevant or potentially relevant mutations and those 
which are not relevant to therapy, as well as making any 
relevant clinical genetics recommendations. As the GRB 
network expands and becomes more interconnected 
with a growing number of referrers using it on a regular 
basis, GRBs will need the facility to communicate in order 
to share practices and experience. Ultimately, the GRB 
makes molecular profiling results clear and accessible to 
the treating physician and patient, increasing the imple-
mentation and use of NGS in clinical practice.
ConClusIon
The SCRI UK/UCL GRB provides an example of a frame-
work which can be implemented for proper use of molec-
ular profiling in clinical practice and in referral to clinical 
trials by generating a system for communication between 
physicians, molecular laboratories and study sites. The 
interpretation of NGS molecular profiling and genera-
tion of appropriate clinical recommendations requires 
a multidisciplinary team with expertise in the analysis 
of sequencing data, clinical cancer genetics and clinical 
trials. Patients as consumers are increasingly aware of the 
availability of such testing platforms, and their percep-
tions and expectations need to be adequately managed.9
The challenge of distinguishing between somatic and 
germline mutations in tumour samples may eventually 
lead to the parallel sequencing of tumour samples and 
matched germline samples as routine in molecular diag-
nostics in collaboration with clinical genetics to follow-up 
results from these analyses. Eventual prospective clin-
ical validation will be needed for cost–benefit analysis of 
employing parallel testing as standard in clinical prac-
tice however, and at present the standard of testing the 
tumour sample alone needs to be interpreted appropri-
ately with clinical genetics expertise on GRBs.
As the SCRI UK GRB network expands, the commu-
nication channels between clinics and study sites will 
increase awareness of study availability, giving patients 
greater access to appropriate clinical trials.
SCMD is now introducing a combined mutation and 
gene fusion panel and has an additional 50-gene panel 
assay, which will provide further data on causal and poten-
tially actionable mutations and oncogenic fusion events. 
With a growing availability of trials and widened molec-
ular profiling, we foresee a greater number of patients 
coming through the GRB to be enrolled in clinical trials 
and an increasing need for GRB review to optimise cancer 
patient stratification.
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